MedTrace Logo

Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)

NCT01017458 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-07-12

No results posted yet for this study

Summary

This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0773 in healthy older men.

Conditions

  • Healthy

Interventions

DRUG

MK0773

Three 25mg oral tablets MK0773 bid, for 12 weeks

DRUG

Comparator: testosterone enanthate

intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks

DRUG

Comparator: placebo oral tablet

placebo oral tablet bid, for 12 weeks

DRUG

Comparator: placebo injection

placebo intramuscular injection q14d, for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01017458 on ClinicalTrials.gov